DIVision of the Interlobar Fissure in Patients Who Do Not Respond to Endobronchial Lung Volume Re… (NCT07682168) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
DIVision of the Interlobar Fissure in Patients Who Do Not Respond to Endobronchial Lung Volume Reduction
15 participantsStarted 2026-08
Plain-language summary
Surgical division of fissure is hypothesized to be safe and feasible. However, there is no preparatory study to test this hypothesis. It is logically expected that morbidity from the procedure could be less than standard LVRS and in preparation to a side-to-side trial of fissure division versus standard LVRS, a safety and feasibility study is required to test this hypothesis and inform future trial design.
Who can participate
Age range
18 Years – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Age \< or equal 75 years
. Stable COPD with less than or equal to 10mg prednisolone daily
. Nonsmoking for 3 months prior to screening and willing to not smoke during the study duration
. Willing and able to complete protocol required study follow-up assessments and procedures
. Fit for thoracoscopy under general anaesthesia (surgical and anaesthetic assessment)
. Recent (\< 18 months) endobronchial lung volume reduction (EBLVR) and lack of response defined by:
. Persistent symptomatic dyspnoea (mMRC \>2) which in the patient's view is no better than baseline
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Number of patients recruited
Timeframe: 18 months
2
Number of patients where surgical division of inter-lobar fissure can be successfully completed
Timeframe: Through study completion (18 months)
3
Number of patients who experience serious adverse events as a result of the intervention
. Absence of target lobar collapse with any residual aeration apparent on imaging
Exclusion criteria
. Fissure completeness \<90% on pre EBLVR StratX (i.e less than 10% of fissure to be divided)
. Chartis positive for collateral ventilation or not performed/not satisfactory at initial EBLVR
. Quantitative perfusion of target lobe \>25% of total on SPECT assessment.
. Previous lung surgery or pleurodesis on the target side for LVR.
. Clinically significant bronchiectasis -greater than 4 tablespoons mucus per day.
. More than 3 COPD exacerbation episodes in the last year.
. Evidence of hypercapnia (pCO2 \>7KPa) - ABG to be performed on admission for index procedure
. Clear evidence of pulmonary hypertension (systolic pulmonary arterial pressure \>45mmHg) or evidence or right ventricular dysfunction as determined by a recent echocardiogram (\<12mo)